Literature DB >> 11920732

Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder.

Joanne Edwards1, Pamela Duncan, James J Going, Amanda D Watters, Kenneth M Grigor, John M S Bartlett.   

Abstract

Following an earlier study linking monosomy 9 with recurrence of transitional cell carcinomas (TCCs) of the urinary bladder, 109 primary and recurrent TCCs (from 47 patients) were examined to explore genetic alterations at chromosome 9 associated with recurrence. Patient DNA was microdissected and extracted from archival tissue sections and analysed for loss of heterozygosity (LOH) at three regions on chromosome 9 where tumour suppressor genes (TSGs) are known to reside (INK 4A, DBC1, and TSC1). Patients were categorized into two groups, non-recurrent TCC (NR, n=18) and recurrent TCC (REC, n=29). It was noted that 12% of NR tumours, compared with 54% of REC primary tumours (p=0.01), had LOH at all informative markers spanning the TSC1 region. The risk of recurrence was significantly higher in patients with deleted TSC1 than in those who retained the TSC1 region (p=0.035). Levels of LOH at DBC1 or INK 4A were not significantly different in NR tumours than in REC primary tumours and recurrence-free survival was not affected by loss of either of these genes. Loss of all informative markers spanning chromosome 9 was observed in 0% of NR tumours compared with 25% of REC primary tumours (p=0.04). The probability of recurrence was also significantly increased in patients who had LOH at all informative markers spanning chromosome 9 (p=0.016), confirming earlier fluorescence in situ hybridization results. This study provides further evidence that recurrence in bladder cancer is a distinct event, with underlying molecular causes. It also identifies the TSC1 locus as a candidate for a TSG, which drives recurrence in a proportion of TCC patients. Loss of all informative markers, including those residing in the TSC1 region, spanning chromosome 9 was also linked to recurrence. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920732     DOI: 10.1002/path.1052

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

2.  Karyometry detects subvisual differences in chromatin organisation state between non-recurrent and recurrent papillary urothelial neoplasms of low malignant potential.

Authors:  M Scarpelli; R Montironi; L M Tarquini; P W Hamilton; A López Beltran; J Ranger-Moore; P H Bartels
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

3.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

4.  Combined lectin- and immuno-histochemistry (CLIH) for applications in cell biology and cancer diagnosis: Analysis of human urothelial carcinomas.

Authors:  Daša Zupančič; Mateja Erdani Kreft; Igor Sterle; Rok Romih
Journal:  Eur J Histochem       Date:  2020-07-01       Impact factor: 3.188

5.  Mutation of the co-chaperone Tsc1 in bladder cancer diminishes Hsp90 acetylation and reduces drug sensitivity and selectivity.

Authors:  Mark R Woodford; Michael Hughes; Rebecca A Sager; Sarah J Backe; Alexander J Baker-Williams; Michael S Bratslavsky; Joseph M Jacob; Oleg Shapiro; Michael Wong; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Oncotarget       Date:  2019-10-08

6.  Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.

Authors:  Louis S Pymar; Fiona M Platt; Jon M Askham; Ewan E Morrison; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2008-04-07       Impact factor: 6.150

7.  Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer.

Authors:  Ui Jae Shim; Il-Seok Lee; Ho Won Kang; Jayoung Kim; Won Tae Kim; Isaac Yi Kim; Keun Ho Ryu; Yung Hyun Choi; Sung-Kwon Moon; Yong-June Kim; Seok-Joong Yun; Sang-Cheol Lee; Wun-Jae Kim
Journal:  Korean J Urol       Date:  2013-09-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.